- Home
- MMA vs AEON Comparison
MMA vs AEON Comparison
Compare MMA & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MMA | AEON |
|---|---|---|
| Founded | 2013 | N/A |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9M | 13.0M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MMA | AEON |
|---|---|---|
| Price | $0.30 | $0.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $1.82 |
| AVG Volume (30 Days) | ★ 2.4M | 1.1M |
| Earning Date | 10-30-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.18 |
| 52 Week High | $1.65 | $1.45 |
Technical Indicators
Market Signals| Indicator | MMA | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 42.95 | 45.47 |
| Support Level | $0.23 | $0.23 |
| Resistance Level | $0.44 | $0.33 |
| Average True Range (ATR) | 0.04 | 0.02 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 37.09 | 20.30 |
Price Performance
Historical ComparisonAbout MMA Alta Global Group Limited
MMA Inc develops technology solutions for the martial arts and combat sports sector. Its platform is designed to support gyms and related businesses by improving areas such as sales channels, customer onboarding, and member engagement. The platform also connects participants, gyms, and communities within the sector, enabling digital management and interaction.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.